Table of contents


On 22 September 2008, orphan designation (EU/3/08/571) was granted by the European Commission to ADIENNE S.r.l., Italy, for recombinant human minibody against complement component C5 for the treatment of atypical haemolytic uraemic syndrome (aHUS) associated with an inherited abnormality of the complement system.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2019 on request of the Sponsor.

In January 2014, ADIENNE S.r.l. changed name to ADIENNE S.r.l.S.U.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Recombinant human minibody against complement component C5
Disease / condition
Treatment of atypical haemolytic uraemic syndrome (aHUS)
Date of first decision
EU designation number

Sponsor's contact details

Via Galileo Galilei, 19
20867 Caponago (MB)
Tel. +39 02 4070 0445
Fax +39 02 9574 5179

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases which includes a directory of patients' organisations registered in Europe.European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating